NCT06349577 Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
| NCT ID | NCT06349577 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,100 participants |
| Start Date | 2025-05-19 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,100 participants in total. It began in 2025-05-19 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.
Eligibility Criteria
Inclusion Criteria: * Able to provide informed consent * Scheduled for elective cardiac surgery with cardiopulmonary bypass Exclusion Criteria * Emergency procedures * Scheduled for heart or lung transplantation * Scheduled for ventricular assist device implantation * Use of the Medtronic Elongated Once-Piece Arterial Cannula * Diagnosed with sepsis * Diagnosed with delirium * Experiencing hemodynamic instability (heart rate \> 100 and systolic blood pressure \< 90) * Requiring mechanical circulatory support * Requiring vasoactive medications
Contact & Investigator
Nathan J Clendenen, MD, MS
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT06349577 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06349577 currently recruiting?
Yes, NCT06349577 is actively recruiting participants. Contact the research team at nathan.clendenen@cuanschutz.edu for enrollment information.
Where is the NCT06349577 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT06349577 clinical trial?
NCT06349577 is sponsored by University of Colorado, Denver. The principal investigator is Nathan J Clendenen, MD, MS at University of Colorado, Denver. The trial plans to enroll 1,100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.